BeOne Medicines (ONC) Receivables - Other (2017 - 2023)

BeOne Medicines (ONC) has 7 years of Receivables - Other data on file, last reported at $1.7 million in Q4 2023.

• Quarterly Receivables - Other fell 42.91% year-over-year to $1.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.7 million (down 42.91% YoY) and the FY2023 annual result came in at $1.7 million, down 42.91% from the prior year.
• Receivables - Other improved to $1.7 million in Q4 2023 per ONC's latest filing, from $1.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $7.2 million in Q3 2021 and bottomed at $1.3 million in Q1 2023.
• The 5-year median for Receivables - Other is $3.4 million (2019), against an average of $4.0 million.
• The widest annual swing landed in 2020, when Receivables - Other jumped 235.96%; it then plunged 74.81% in 2023.
• Tracing ONC's Receivables - Other over 5 years: stood at $1.7 million in 2019, then surged by 283.93% to $6.6 million in 2020, then retreated by 23.67% to $5.1 million in 2021, then plunged by 39.85% to $3.0 million in 2022, then slumped by 42.91% to $1.7 million in 2023.
• Per Business Quant, the three latest ONC Receivables - Other figures stand at $1.7 million (Q4 2023), $1.6 million (Q3 2023), and $2.0 million (Q2 2023).

Peer Comparison